Replacement - Holding(s) in Company
Integrated Diagnostics Holdings plc announced an amendment to a previous notification regarding major shareholdings. Elliott Investment Management, L.P., through its subsidiary Actis IDH Limited, now holds 126,000,000 voting rights, representing 21.67% of the company's shares, following the completion of a transaction conditional on regulatory clearance received on March 31, 2026. This transaction, an indirect share sale, will settle on April 9, 2026.
Select text to share a quote on X · sign in to keep highlights & notes in your IDHC notes
The following amendment has been made to the announcement released on 8 April 2026 at 17:50:52 under RNS Number 7095Z.
The resulting situation on the date on which threshold was crossed or reached has been changed to 126,000,000.
All other details remain unchanged.
TR-1: Standard form for notification of major holdings
- Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
| Non-UK issuer | X |
- Reason for the notification (please mark the appropriate box or boxes with an "X")
| An acquisition or disposal of voting rights | X |
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii :
Details of person subject to the notification obligation iv
| Name | Elliott Investment Management, L.P. |
| City and country of registered office (if applicable) | Delaware |
Full name of shareholder(s) (if different from 3.) v
| Name | Actis IDH Limited |
| City and country of registered office (if applicable) | St Peter Port, Guernsey |
| 5. Date on which the threshold was crossed or reached vi : | 31 March 2026 |
| 6. Date on which issuer notified (DD/MM/YYYY): | 8 April 2026 |
- Total positions of person(s) subject to the notification obligation
| Resulting situation on the date on which threshold was crossed or reached | 21.67% | N/A | 21.67% | 126,000,000 |
| Position of previous notification (if applicable) | N/A | N/A | N/A | |
| A: Voting rights attached to shares | ||||
| Class/type of shares ISIN code (if possible) | Number of voting rights ix | % of voting rights | ||
| Direct (DTR5.1) | Indirect (DTR5.2.1) | Direct (DTR5.1) | Indirect (DTR5.2.1) | |
| Ordinary | N/A | 126,000,000 | N/A | 21.67% |
| SUBTOTAL 8. A | 126,000,000 | 21.67% | ||
| B 1: Financial Instruments according to DTR5.3.1R (1) (a) | ||||
| N/A | N/A | N/A | N/A | N/A |
| SUBTOTAL 8. B 1 | N/A | N/A | ||
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
| N/A | N/A | N/A | N/A | N/A | N/A |
| SUBTOTAL 8.B.2 | N/A | N/A | |||
| Paul Singer | 19.28% | 19.28% | |||
| Elliott Investment Management GP LLC | 19.28% | 19.28% | |||
| Elliott Investment Management LP | 19.28% | 19.28% | |||
| Elliott International Limited | 13.04% | 13.04% | |||
| Elliott International, L.P. | 13.26% | 13.26% | |||
| Elliott Associates, L.P. | 6.24% | 6.24% | |||
| Devonian ICAV, acting solely on behalf of its sub-fund, Devonian Fund V | 19.50% | 19.50% | |||
| Ribbon Ventures Limited | 21.67% | 21.67% | |||
| Actis IDH Limited | 21.67% | 21.67% |
In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
Additional information xvi
As announced on 13 November 2025 by Integrated Diagnostics Holdings plc (the "Company"), Actis GP LLP and Actis Guernsey GP Limited, each, a subsidiary of Actis LLP and which through funds under their management control shares representing 21.67% of the Company (the "Actis Shareholding"), have agreed to dispose, by way of an indirect share sale of Actis IDH Limited, of the entire Actis Shareholding to a special purpose vehicle, the majority of which is controlled by funds managed by Elliott Investment Management L.P. (the "Transaction"). The Transaction, which at the time of the announcement was conditional on the receipt of regulatory clearance (which was received on 31 March 2026, at which point the transfer became unconditional), will settle on Thursday 9 April 2026.
| Place of completion | London, United Kingdom |
| Date of completion | 8 April 2026 |
Notes
Name of ultimate controlling person A (chain 1)
Name of controlled undertaking B
Name of controlled undertaking C
Name of ultimate controlling person A (chain 2)
Name of controlled undertaking B
Name of controlled undertaking D
Name of ultimate controlling person A (chain3)
Name of controlled undertaking E
Name of controlled undertaking F
xvi Example: Correction of a previous notification.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.